Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population
- 6 February 2018
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (1), 213-215
- https://doi.org/10.1111/bjd.16427
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer, 2017
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabClinical Cancer Research, 2016
- Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapyOncotarget, 2016
- The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanomaCancer Medicine, 2016
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabAnnals of Oncology, 2016
- Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanomaBritish Journal of Cancer, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaThe New England Journal of Medicine, 2015
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010